2 May 2007, London, UK: Ark Therapeutics Group plc announces that it has filed its application to the US Recombinant DNA Advisory Committee (RAC) to obtain clearance for its planned Phase III US clinical study of Trinam(R), Ark’s novel gene-based therapy to prevent haemodialysis access graft blockage.
